{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:34:04Z","timestamp":1792791244522,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministero della Salute, Italy","award":["CORR24"],"award-info":[{"award-number":["CORR24"]}],"id":[{"id":"https:\/\/ror.org\/00789fa95","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-88494-3","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:55:11Z","timestamp":1738713311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Detecting gene copy number alterations by Oncomine Comprehensive genomic profiling in a comparative study on FFPE tumor samples"],"prefix":"10.1038","volume":"15","author":[{"given":"Fabio","family":"Bozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Dagrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ardore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Penso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Costanza","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e8 Viola","family":"Trupia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Busico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tamborini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vingiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"88494_CR1","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","volume":"45","author":"G Ciriello","year":"2013","unstructured":"Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127\u20131133 (2013).","journal-title":"Nat. Genet."},{"key":"88494_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0027-5107(97)00314-X","volume":"401","author":"MP Douglas","year":"1998","unstructured":"Douglas, M. P. & Rogers, S. O. DNA damage caused by common cytological fixatives. Mutat. Res. 401, 77\u201388 (1998).","journal-title":"Mutat. Res."},{"key":"88494_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1126\/science.aai8690","volume":"355","author":"L Chen","year":"2017","unstructured":"Chen, L., Liu, P., Evans, T. C. Jr & Ettwiller, L. M. DNA damage is a pervasive cause of sequencing errors, directly confounding variant identification. Science 355, 752\u2013756 (2017).","journal-title":"Science"},{"key":"88494_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00428-019-02555-3","volume":"474","author":"A Eijkelenboom","year":"2019","unstructured":"Eijkelenboom, A. et al. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. Virchows Arch. 474, 673\u2013680 (2019).","journal-title":"Virchows Arch."},{"key":"88494_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","volume":"82","author":"T Hu","year":"2021","unstructured":"Hu, T., Chitnis, N., Monos, D. & Dinh, A. Next-generation sequencing technologies: An overview. Hum. Immunol. 82, 801\u2013811 (2021).","journal-title":"Hum. Immunol."},{"key":"88494_CR6","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1038\/nmeth.1374","volume":"6","author":"P Medvedev","year":"2009","unstructured":"Medvedev, P., Stanciu, M. & Brudno, M. Computational methods for discovering structural variation with next-generation sequencing. Nat. Methods. 6, S13\u201320 (2009).","journal-title":"Nat. Methods"},{"key":"88494_CR7","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1093\/bioinformatics\/bts535","volume":"28","author":"SM Teo","year":"2012","unstructured":"Teo, S. M., Pawitan, Y., Ku, C. S., Chia, K. S. & Salim, A. Statistical challenges associated with detecting copy number variations with next-generation sequencing. Bioinformatics 28, 2711\u20132718 (2012).","journal-title":"Bioinformatics"},{"key":"88494_CR8","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1101\/gr.175141.114","volume":"24","author":"I Scheinin","year":"2014","unstructured":"Scheinin, I. et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 24, 2022\u20132032 (2014).","journal-title":"Genome Res."},{"key":"88494_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/jmp4020012","volume":"4","author":"CI Dumur","year":"2023","unstructured":"Dumur, C. I. et al. Analytical Validation and clinical utilization of the Oncomine Comprehensive Assay Plus Panel for Comprehensive genomic profiling in solid tumors. J. Mol. Pathol. 4, 109\u2013127 (2023).","journal-title":"J. Mol. Pathol."},{"key":"88494_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41241-016-0007-3","volume":"37","author":"HS Jung","year":"2017","unstructured":"Jung, H. S., Lefferts, J. A. & Tsongalis, G. J. Utilization of the oncoscan microarray assay in cancer diagnostics. Appl. Cancer Res. 37, 1\u20138 (2017).","journal-title":"Appl. Cancer Res."},{"key":"88494_CR11","unstructured":"Schmidt, J. et al. A new method for high fidelity copy number analysis in solid tumor samples and its implementation in the OncoScan\u2122 FFPE assay kit; (Abstract 3300), Presented at the Annual Meeting of the American Society of Human Genetics, October 18\u201322, San Diego California (2014)."},{"key":"88494_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12920-015-0079-z","volume":"8","author":"JM Foster","year":"2015","unstructured":"Foster, J. M. et al. Crosslaboratory validation of the OncoScan\u00ae FFPE assay, a multiplex tool for whole genome tumour profiling. BMC Med. Genomics. 8, 5 (2015).","journal-title":"BMC Med. Genomics"},{"key":"88494_CR13","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast Cancer: ASCO-College of American Pathologists Guideline Update. J. Clin. Oncol. 41, 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"key":"88494_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14737159.2018.1440210","volume":"18","author":"CC Volpi","year":"2018","unstructured":"Volpi, C. C. et al. Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients. Expert Rev. Mol. Diagn. 18, 259\u2013277 (2018).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"88494_CR15","doi-asserted-by":"publisher","first-page":"918317","DOI":"10.3389\/fphar.2022.918317","volume":"13","author":"D Liu","year":"2022","unstructured":"Liu, D. et al. LY2874455 and Abemaciclib Reverse FGF3\/4\/19\/CCND1 amplification mediated Gefitinib Resistance in NSCLC. Front. Pharmacol. 13, 918317 (2022).","journal-title":"Front. Pharmacol."},{"key":"88494_CR16","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. Framework to rank genomic alterations as targets for cancer precision medicine: The ESMO scale for clinical actionability of molecular targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"88494_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele, M. F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: A report from the ESMO Precision Medicine Working Group. Ann. Oncol. 35, 588\u2013606 (2024).","journal-title":"Ann. Oncol."},{"key":"88494_CR18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1101\/gr.114876.110","volume":"6","author":"A Abyzov","year":"2011","unstructured":"Abyzov, A., Urban, A. E., Snyder, M. & Gerstein, M. CNVnator: An approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res. 6, 974\u2013984 (2011).","journal-title":"Genome Res."},{"key":"88494_CR19","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1093\/nar\/gks001","volume":"40","author":"Y Benjamini","year":"2012","unstructured":"Benjamini, Y. & Speed, T. P. Summarizing and correcting the GC content bias in high-throughput sequencing. Nucleic Acids Res. 40, e72 (2012).","journal-title":"Nucleic Acids Res."},{"key":"88494_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nbt821","volume":"21","author":"P Hardenbol","year":"2003","unstructured":"Hardenbol, P. et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat. Biotechnol. 21, 673\u2013678 (2003).","journal-title":"Nat. Biotechnol."},{"key":"88494_CR21","first-page":"5230","volume":"13","author":"LK Vestergaard","year":"2021","unstructured":"Vestergaard, L. K., Oliveira, D. N. P., Poulsen, T. S., H\u00f8gdall, C. K. & H\u00f8gdall, E. V. Oncomine\u2122 Comprehensive Assay v3 vs. Oncomine\u2122 Compr. Assay. Plus Cancers. 13, 5230 (2021).","journal-title":"Oncomine\u2122 Compr. Assay. Plus Cancers"},{"key":"88494_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00124","volume":"3","author":"T Al Baghdadi","year":"2019","unstructured":"Al Baghdadi, T. Et al.Palbociclib in patients with pancreatic and biliary Cancer with CDKN2A alterations: Results from the targeted Agent and profiling utilization Registry Study. JCO Precis Oncol. 3, 1\u20138 (2019).","journal-title":"JCO Precis Oncol."},{"key":"88494_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00383","volume":"3","author":"J Peguero","year":"2019","unstructured":"Peguero, J. et al. Tissue\/Site-Agnostic study of Ribociclib for Tumors with cyclin D-CDK4\/6 pathway genomic alterations: A phase II, Open-Label, single-arm Basket Study. JCO Precis Oncol. 3, 1\u201310 (2019).","journal-title":"JCO Precis Oncol."},{"key":"88494_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/PO.20.00037","volume":"4","author":"ER Ahn","year":"2020","unstructured":"Ahn, E. R. Et al. Palbociclib in patients with non-small-cell Lung Cancer with CDKN2A alterations: Results from the targeted Agent and profiling utilization Registry Study. JCO Precis Oncol. 4, 757\u2013766 (2020).","journal-title":"JCO Precis Oncol."},{"key":"88494_CR25","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner, N. C. Et al. Inavolisib-based therapy in PIK3CA-Mutated advanced breast Cancer. N Engl. J. Med. 391, 1584\u20131596 (2024).","journal-title":"N Engl. J. Med."},{"key":"88494_CR26","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom, L. D. et al. MRTX1719 is an MTA-Cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-Deleted Cancer. Cancer Discov. 13, 2412\u20132431 (2023).","journal-title":"Cancer Discov"},{"key":"88494_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/03008916211062266","volume":"108","author":"L Incorvaia","year":"2022","unstructured":"Incorvaia, L., Russo, A. & Cinieri, S. The molecular tumor board: A tool for the governance of precision oncology in the real world. Tumori 108, 288\u2013290 (2022).","journal-title":"Tumori"},{"key":"88494_CR28","doi-asserted-by":"publisher","first-page":"e2300067","DOI":"10.1200\/PO.23.00067","volume":"7","author":"A Vingiani","year":"2023","unstructured":"Vingiani, A. et al. Molecular Tumor Board as a clinical Tool for converting Molecular Data Into Real-World patient care. JCO Precis Oncol. 7, e2300067 (2023).","journal-title":"JCO Precis Oncol."},{"key":"88494_CR29","unstructured":"Gassmann, M. DNA Integrity Number (DIN) with the Agilent 2200 Tape Station System and the Agilent Genomic DNA ScreenTape Assay. Agilent technologies. (2015). https:\/\/www.agilent.com\/cs\/library\/applications\/5991-5258EN.pdf"},{"key":"88494_CR30","unstructured":"Jung, H., Ji, S., Song, S. & Park, J. The DNA Integrity Number (DIN) Provided by the Genomic DNA ScreenTape Assay Allows for Streamlining of NGS on FFPE Tissue Samples. Agilent technologies. (2014). https:\/\/hpst.cz\/sites\/default\/files\/oldfiles\/dna-integrity-number-din-provided-genomic-dna-screentape-assay-allo"},{"key":"88494_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/01621459.1972.10481279","volume":"67","author":"DF Bauer","year":"1972","unstructured":"Bauer, D. F. Constructing confidence sets using Rank statistics. J. Am. Stat. Ass. 67, 687\u2013690 (1972).","journal-title":"J. Am. Stat. Ass"},{"key":"88494_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.37349\/etat.2022.00102","volume":"3","author":"I Capone","year":"2022","unstructured":"Capone, I. et al. Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: Assessment of bioinformatic tools reliability in FFPE samples. Explor. Target. Antitumor Ther. 3, 582\u2013597 (2022).","journal-title":"Explor. Target. Antitumor Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88494-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:55:18Z","timestamp":1738713318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88494-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88494"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88494-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4314"}}